Condition: CML (Chronic Myelogenous Leukemia) · Chronic Phase CML · Sponsor: Enliven Therapeutics
The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in Japanese patients with chronic phase chronic myeloid leukemia with and without T315I mutations in patients who has failed, or the patient is intolerant to, or not a candidate for, at least 2 prior TKIs.
This description comes directly from the study's public registry record.
Yuzo Tomonaga · +81-3-6779-8000 · ClinicalTrialInformation@cmic.co.jp
Always discuss trial participation with your own doctor first.
| Akita University Hospital | Akita, Akita, Japan | Recruiting |
| Aiiku Hospital | Sapporo, Hokkaido, Japan | Recruiting |
| The University of Osaka Hospital | Suita-shi, Osaka, Japan | Recruiting |
| Tokyo Medical University Hospital | Shinjuku-ku, Tokyo, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06787144